To prevent potential overtreatment of metastatic non-small cell lung cancer, the individual parameters of circulating hematopoietic stem cells (HSCs) (percentage of CD133 + HSCs, CD34 + HSCs, and mitotic activity in the circulating lymphocyte fraction) were measured before conventional cytotoxic therapy in 35 patients by flow cytometry and then compared retrospectively with their individual survival periods. The plot of dependence of the CD133 + HSC × mitotic activity product versus CD34 + HSC revealed the prognostic properties during the survival period (range 0.3 -124 months). Discrimination of patients with an expected survival shorter than 12 months was possible based on the positions of individual points on the plot, with a sensitivity and specificity of ~100 each and a diagnostic odds ratio of 1250. The evaluation of individual lymphoproliferative resources before cytotoxic treatment may be useful for the optimal therapeutic compromise between the desired inhibition of malignant target cells and the life-threatening depression of lymphocytopoiesis.
Introduction
Upon receiving a diagnosis of a fatal illness, such as metastatic cancer, a reasonable question is how much time the patient has left to live. The answer is important for patients with fatal non-small cell lung cancer (NSCLC) because of the high probability that subsequent anticancer treatment may bring about a poorer result compared with palliative therapy or even the absence of treatment [1] [2] [3] [4] [5] . The survival rate and median survival can be used to determine the potential benefits of therapy but cannot predict what will happen for an individual patient, as they are based on previous outcomes of large numbers of patients. Comorbidities are also associated with inferior overall survival, but a single patient may survive for as long as several months or years [6] .
The performance status (PS) of patients is significantly associated with the cumulative survival, defined by the survival rate and median survival. Even after adjustment for performance status, some patients show much longer or shorter survival than expected [7] [8] . Recent studies showed that a high neutrophil-to-lymphocyte ratio in the blood is a useful prognostic factor for poor overall survival of patients with lung cancer [9] [10], but this does not solve the problem of individual prediction, because the survival period of patients with a similar neutrophil-to-lymphocyte ratio after conventional treatment is highly variable over the range of 1 -60 months [11] . Therefore, accurate prediction of life expectancy in terminally ill patients continues to be challenging.
The current rationale for the volume of cytotoxic therapy does not take into account functional deterioration of the hematopoietic tissue proliferative resource caused by the previous cancer progression, even though a similar deterioration is the main cause of premature aging and reduced life expectancy even in the absence of a tumor [12] . The lowest level of permissible clinical lymphocytopenia (0.5 × 10 9 /L) induced by treatment [13] on the one hand and the success of conventional cytotoxic therapy on the other hand are not compatible with stimulation of anticancer immunity, and the safety of the procedure is often simply ignored. Therefore, practical assessment of individual lymphocytopoietic resources in the clinic is required to achieve optimal therapeutic compromise between the desired inhibition of malignant target cells and myelodepression, which accelerates the onset of life-threatening cachexia [14] . Recent data indicate that the health condition and level of fitness of individual patients markedly influence the morphogenic function of circulating stem cells of bone marrow origin (HSCs), which migrate to many different tissues, including those that are malignant, and stimulate proliferation, regeneration, and repair [15] 
Mortality Rates
Survival curves for each subgroup were approximated using exponential curve fitting in Excel [21] with the following Equation (1):
where S t is the proportion of surviving patients at any point during the 10-year period, t is the time (months) after the beginning of therapy, k and λ are the exponential mortality rates per month, A and B are the proportions of patients who died corresponding with a monthly mortality rate = k or λ, and C is the proportion of patients who did not die during the extended 10-year follow-up period.
Blood Samples for Flow Cytometry
A parallel study of blood samples was conducted 1 -2 days before the start of chemoradiotherapy in 35 patients with lung cancer (average age 66.2 ± 1.1 years, 13 women, 22 men) who provided written informed consent. A separate group of 16 adult volunteers without any malignancies (average age 61 years, 7 women, 9 men) was included to obtain control (baseline) data.
Immediately after collection of peripheral blood (10 mL), the mononuclear cell fraction (MNC) was isolated by classical Ficoll density separation [22] , omitting the final step of magnetic cell enrichment. Viability was assessed using the trypan blue exclusion test.
Cells from two equal portions of the fresh MNC fraction were stained for flow cytometric analysis. The nucleic acid stain Hoechst 33342 (bis-benzimidazole fluorochrome; Sigma-Aldrich, St. Louis, MO, USA) was used for cell cycle analysis, which was performed as described previously [23] with slight modifications. 
Flow Cytometry
The 
Flow Cytometric Analysis
A minimum of 500,000 total events were recorded twice when CD34 + and 
Kinetic and Statistical Analyses
The goal was to identify specific features in cell parameters prior to commencement of treatment, which may reliably distinguish patients with different survival periods. We defined the functions that best described the trends in the parameters according to survival by searching for appropriate equations [21] . Kinetic 
Results

Analysis of Survival Curve
According to Figure 1 and Equation (1), current survival S t was calculated as follows: Figure 2 shows the differences in the cell parameters of peripheral lymphocytes with time from cytometric analysis to death (i.e., survival period).
Cytokinetic Parameters
Decreases in CD34 + HSC, mitotic (Mt) cells and RA proportions were strongly confirmed with p < 0.001 (all approximating equations are shown in the plot).
The relationship between the product of Mt × CD133 + (RA) and the CD34 + proportions is shown in Figure 3 .
The second-order polynomial approximation indicates that dependency RA from CD34 + (double common line in Figure 3 (Table 1) .
Remarkably, the turbulence of the points inside each of the two branches in Figure 3 was not similar. The coefficients of variation (CV) for four parameters (CD34 + HSC, Mt, CD133 + HSC, and RA) were higher for the patients surviving < 12 months compared with ≥12 months (Table 1) . The difference (p = 0.014, Fisher's exact test) indicated greater turbulence in bone marrow reproductive potency during the last year of the life. Therefore, the predictive power of the plot in Figure 3 is limited by the differences between subgroups A and (B + C).
The mean parameters of both subgroups revealed abnormally high lymphocytopoiesis activity compared with those of healthy controls (Table 2) Table 1 and Table 2. values compared with those who survived for ≥12 months (n = 14/35). The median survival in the two subgroups differed by ~7-fold (4.6 months vs. 31.5 months, respectively).
Using the data shown in Figure 3 , discrimination of individual patients with a predicted survival < 12 months appeared to be accurate, with a sensitivity and specificity of ~100% each. The DORs for prediction of individual survival < 12 months was calculated based on these data using a 2 × 2 confusion matrix, as described previously [25] , yielding a value of 1250 (95% confidence interval 640 -2450; log DOR ± log SE DOR = 7.13 ± 0.34). . In naturally aged bone marrow the progenitor cells are skewed toward myeloid cell production with an inevitably strong deficit in lymphohematopoietic progenitor and stem cells [28] .
Discussion
The incidence, mortality, and prevalence of 24 major types of malignancy during natural frailty decrease abruptly with age [29] .
These results strongly contradict the concept of anticancer immunity but con- Table 1, CV) .
Qualitatively, a moderate turbulent phase and strong hyperactivity (2 -8-fold) of lymphocytopoiesis in NSCLC patients are observed over a long period (~50 months, Figure 2 ), which rapidly exhaust the system during the last year of life [14] . A concomitant worsening of prognosis is reflected in the decreased number of CD133 + HSCs compared with healthy controls (Table 2 ) and in the change from a positive to a negative relationship between CD34 + HSC numbers and RA.
As shown in Figure 3 , poor prognosis is accompanied by the inability of lymphocytopoiesis to maintain high levels of CD34 + , CD133 + , and Mt production simultaneously, as seen in the long survival period group. The transition from one state of lymphocytopoiesis to another is accompanied by increased "turbulence" (Figure 2 and CV < 12/CV ≥ 12, M < 12/M ≥ 12 parameters in Table 1 ).
Both subtypes of "turbulence" in Figure 3 arise from the asymmetrical cell division, which is typical for ideal (steady-state) cell production with a lower CV [37] . As reported previously [30] , the "turbulence" of lympho-hematopoiesis and probability of death increase with the rate of cell loss in bone marrow, especially in the most vulnerable pools of lymphocytes and HSCs. Remarkably, the benefits of systemic therapy in terms of survival followed obviously by post-treatment lymphocytopenia which indicate the weakening of the tumor trophic support. The therapy becomes ineffective if the lymphocytopenia drops below its "therapeutic" limit during treatment, or if the basic lymphocytopenia before therapy is lower of this limit [38] [39].
Conclusion
Cytotoxic therapy has both advantages and disadvantages, because it not only kills cancer cells but also adversely affects the physiological systems responsible for maintaining the viability of the host organism. The prevalence of one over the other effect depends on the ratio of basic lymphoproliferative potency in the patient and the cumulative dose of systemic hematosuppressive therapy; higher potency is associated with a longer period during which the therapy may be successful, and vice versa. Thus, predicting individual treatment outcomes is not possible, and evaluation of lymphoproliferative resources prior to beginning cytotoxic treatment may be beneficial for reliable discrimination of subgroup of patients with an expected survival shorter than 12 months. According our data, the probability of such discrimination reaches to a sensitivity and specificity of ~100% each. Limited number of patients involved in this investigation suggests the necessity of further test of this approach in clinic.
